S-024
HU-210 solution
100 μg/mL in methanol, ampule of 1 mL, (Spice Cannabinoid), certified reference material, Cerilliant®
InChI key
SSQJFGMEZBFMNV-WOJBJXKFSA-N
InChI
1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m1/s1
SMILES string
CCCCCCC(C)(C)c1cc(O)c2[C@@H]3CC(CO)=CC[C@H]3C(C)(C)Oc2c1
grade
certified reference material
Quality Level
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
drug control
Narcotic Licence Schedule E (Switzerland)
concentration
100 μg/mL in methanol
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
format
single component solution
storage temp.
−20°C
General description
HU-210 is a synthetic cannabinoid found in the herbal mixture “Spice.” Illicit use of this Spice cannabinoid includes smoking the herbal product to obtain a psychoactive effect. Structurally similar to (-)-Δ8-THC and 11-Hydroxy-Δ9-THC, HU-210 is considerably more potent than natural THC from cannabis and has an extended duration of action.
In July, 2009, the US Drug Enforcement Agency (DEA) placed HU-210 on its Drugs and Chemicals of Concern list. Since HU-210′s placement on this list, DEA has reported seizures of Spice herbal mixtures in Ohio and Florida. HU-210 is currently listed as a Schedule I controlled substance. In recognition of this regulatory challenge, Cerilliant supplies its certified HU-210 reference standard in a convenient, quantitative, DEA-exempt solution.
In July, 2009, the US Drug Enforcement Agency (DEA) placed HU-210 on its Drugs and Chemicals of Concern list. Since HU-210′s placement on this list, DEA has reported seizures of Spice herbal mixtures in Ohio and Florida. HU-210 is currently listed as a Schedule I controlled substance. In recognition of this regulatory challenge, Cerilliant supplies its certified HU-210 reference standard in a convenient, quantitative, DEA-exempt solution.
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes
存储类别
3 - Flammable liquids
wgk
WGK 1
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
监管及禁止进口产品
此项目有
Adrianne R Wilson-Poe et al.
Pharmacology, biochemistry, and behavior, 103(3), 444-449 (2012-10-16)
Co-administration of opioids and cannabinoids can enhance pain relief even when administered on different days. Repeated systemic administration of morphine has been shown to enhance the antinociceptive effect of tetrahydrocannabinol (THC) administered 12h later, and repeated microinjection of the cannabinoid
L N Maslov et al.
Eksperimental'naia i klinicheskaia farmakologiia, 75(12), 15-18 (2012-01-01)
It was shown that perfusion of the isolated heart of rat with solution containing the CB1- and CB2-receptor agonist HU-210 at concentrations of 0.1 or 1.0 microM/L for a duration of 10 min at 20 min before global ischemia (45
Valentina Chiodi et al.
Neurobiology of disease, 45(3), 983-991 (2011-12-31)
Cannabinoid CB1 receptors (CB1Rs) are known to be downregulated in patients and in animal models of Huntington's disease (HD). However, the functional meaning of this reduction, if any, is still unclear. Here, the effects of the cannabinoid receptor agonist WIN
Ming-hua Cao et al.
PloS one, 7(12), e52921-e52921 (2013-01-04)
Acute pancreatitis (AP), especially severe acute pancreatitis often causes extra-pancreatic complications, such as acute gastrointestinal mucosal lesion (AGML) which is accompanied by a considerably high mortality, yet the pathogenesis of AP-induced AGML is still not fully understood. In this report
Unyong Kim et al.
Journal of pharmaceutical and biomedical analysis, 64-65, 26-34 (2012-03-13)
(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210) is a synthetic cannabinoid, with a classical cannabinoid structure similar to Δ(9)-tetrahydrocannabinol (Δ(9)-THC). In this study, the in vitro metabolism of HU-210 was investigated in human liver microsomes to characterize associated phase I metabolites. HU-210 was incubated with
相关内容
HPLC Analysis of Synthetic (Spice) Cannabinoids on AscentisR Express F5
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持